<DOC>
	<DOCNO>NCT00266227</DOCNO>
	<brief_summary>This Phase III , randomize , double-blind , placebo-controlled , multicenter study evaluate efficacy retreatment rituximab subject active rheumatoid arthritis ( RA ) receive Methotrexate ( MTX ) .</brief_summary>
	<brief_title>A Study Retreatment With Rituximab Patients With Rheumatoid Arthritis Receiving Background Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Signed informed consent form Ability willingness comply requirement study protocol Age 1880 year Diagnosis RA least 6 month Receiving treatment RA outpatient basis Documented moderate severe active RA activity screen Day 1 Documented inadequate response previous current treatment one following : etanercept , infliximab , and/or adalimumab toxicity inadequate efficacy Use MTX 1025 mg/wk ≥ 12 week prior Day 1 stable dose ≥ 4 week Willingness receive oral folic acid If take background corticosteroid , use corticosteroid must stable dose 4 week prior Day 1 Use one NSAID permit dose stable ≥ 2 week prior Day 1 For men woman reproductive potential , willingness use reliable mean contraception ≥ 30 day prior Day 1 study duration duration subject 's peripheral CD19 B cell deplete , whichever longer Rheumatic autoimmune disease RA significant systemic involvement secondary RA ; Secondary Sjogren 's syndrome RA permit . History current inflammatory joint disease RA systemic rheumatic disorder ( e.g. , systemic lupus erythematosus , inflammatory bowel disease , scleroderma , inflammatory myopathy , overlap syndrome ) History deep space/tissue infection within 52 week prior Day 1 Diagnosis juvenile idiopathic arthritis ( JIA ) , juvenile rheumatoid arthritis ( JRA ) , and/or RA age 16 Functional Class IV , define ACR Classification Functional Status Rheumatoid Arthritis Any surgical procedure , include bone/joint surgery/synovectomy ( include joint fusion replacement ) , within 12 week prior Day 1 plan within 48 week Day 1 Known hypersensitivity component humanize murine monoclonal antibody Receipt vaccination within 4 week prior Day 1 Significant cardiac pulmonary disease , include obstructive pulmonary disease Evidence significant uncontrolled concomitant disease , , limit nervous system , renal , hepatic , endocrine , gastrointestinal disorder Known active bacterial , viral , fungal , mycobacterial , infection ( include tuberculosis atypical mycobacterial disease exclude fungal infection nail bed ) major episode infection require hospitalization treatment IV antibiotic within 4 week Day 1 oral antibiotic within 2 week Day 1 History serious recurrent chronic infection ( chest Xray perform screen one perform within 12 week screen show clinically significant abnormality ) History currently active primary secondary immunodeficiency , include HIV infection History cancer , include solid tumor hematologic malignancy ( except basal cell squamous cell carcinoma skin excise cure ) History significant cytopenia bone marrow disorder History alcohol , drug , chemical abuse within 24 week prior Day 1 Pregnancy lactation Neuropathies neurovasculopathies might interfere pain evaluation Poor peripheral venous access Intolerance contraindication oral IV corticosteroid Positive hepatitis B surface antigen hepatitis C antibody serology For woman childbearing potential ( include tubal ligation ) , positive serum pregnancy test screen Current use DMARD MTX Concurrent treatment biologic agent Treatment investigational agent within 4 week prior Day 1 five halflives investigational drug ( whichever longer ) Any previous treatment rituximab celldepleting therapy , include CAMPATH , antiCD4 , antiCD5 , antiCD3 , antiCD19 , antiCD11a , antiCD22 , antiBLys/ BAFF , antiCD20 agent Previous treatment costimulation block agent , include abatacept Previous treatment anti &lt; alpha &gt; 4 integrin agent , include natalizumab Previous treatment within 6 month screen IV &amp; globulin Prosorba ( R ) Column Intraarticular parenteral corticosteroid within 4 week prior Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>